DrugPatentWatch Database Preview

Details for Patent: 6,812,238

« Back to Dashboard

Which drugs does patent 6,812,238 protect, and when does it expire?

Patent 6,812,238 protects CRESEMBA and is included in two NDAs.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 6,812,238

Title:	N-substituted carbamoyloxyalkyl-azolium derivatives
Abstract:	N-substituted carbamoyloxyalkyl-azolium derivatives which have antifungal activity and are useful for the treatment of fungal diseases.
Inventor(s):	Fukuda; Hiroshi (Tokyo, JP), Hayase; Tadakatsu (Chigasaki, JP), Mizuguchi; Eisaku (Kamakura, JP), Shimma; Nobuo (Chigasaki, JP), Ohwada; Jun (Kamakura, JP), Oikawa; Nobuhiro (Kawasaki, JP), Sakaitani; Masahiro (Chigasaki, JP), Tsukazaki; Masao (Fujisawa, JP), Umeda; Isao (Yokohama, JP)
Assignee:	Basilea Pharmaceutica AG (Binningen, CH)
Application Number:	09/702,944
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 6,812,238
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 6,812,238

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	CRESEMBA	isavuconazonium sulfate	CAPSULE;ORAL	207500-001	Mar 6, 2015		RX	Yes	Yes				Y
Astellas	CRESEMBA	isavuconazonium sulfate	POWDER;INTRAVENOUS	207501-001	Mar 6, 2015		RX	Yes	Yes				Y

International Family Members for US Patent 6,812,238

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	029403
Austria	291575
Australia	2835201
Australia	777859